EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Oral Psoriasis Therapies

JaBreia James, Tracey Otto, Julia Gao, Martina L Porter

Dermatologic Clinics · 2024

DOI: 10.1016/j.det.2024.02.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Dermatologic Clinics, 2024. Verfasst von JaBreia James und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Combined Dermatology Residency Program, Department of Dermatology, Harvard Medical School, 55 Fruit Street, BH 616 Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Acitretin, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AbbVie, Johnson & Johnson Innovative Medicine, National Psoriasis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral psoriasis therapies include both older traditional immunosuppressants, such as methotrexate, cyclosporine, and acitretin, as well as newer, more targeted agents, such as apremilast, deucravacitinib, and oral interleukin-23 receptor antagonists. Patients may prefer oral therapies to injectable therapies based on the route of administration. Both older and newer oral psoriasis therapies can be utilized effectively in the treatment of psoriasis. Here, we will review oral agents used in the treatment of psoriasis as well as provide commentary on their role in our current, evolving psoriasis treatment paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisThalidomideAcitretinImmunosuppressive AgentsMethotrexateCyclosporineDermatologic AgentsHumansAdministration, OralPiperidinesPyrazolesPyrimidinesPyrrolesAntibodies, Monoclonal, HumanizedKeratolytic AgentsIndolesNicotinic AcidsAntibodies, Monoclonal

Stichwörter der Autor:innen

AcitretinBaricitinibCyclosporineJak inhibitorsMethothrexatePsoriasisPsoriatic arthritisTofacitinib

Substanzen

apremilastThalidomideAcitretinImmunosuppressive AgentsMethotrexateCyclosporineDermatologic AgentsPiperidinesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Harvard Combined Dermatology Residency Program, Department of Dermatology, Harvard Medical School, 55 Fruit Street, BH 616 Boston, MA 02114, USA.
  • Department of Dermatology, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA.
  • Department of Dermatology, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA; Department of Dermatology, Harvar…

Förderung

  • AbbVie
  • Johnson & Johnson Innovative Medicine
  • National Psoriasis Foundation

Zitieren

APA

James, J., Otto, T., Gao, J., & Porter, M. L. (2024). Oral Psoriasis Therapies. Dermatologic Clinics. https://doi.org/10.1016/j.det.2024.02.013

Vancouver

James J, Otto T, Gao J, Porter ML. Oral Psoriasis Therapies. Dermatologic Clinics. 2024. doi:10.1016/j.det.2024.02.013

BibTeX
@article{James2024,
  author = {James, JaBreia and Otto, Tracey and Gao, Julia and Porter, Martina L},
  title = {Oral Psoriasis Therapies},
  journal = {Dermatologic Clinics},
  year = {2024},
  doi = {10.1016/j.det.2024.02.013}
}
Kostenlos starten →